Illinois Biotechnology Industry Organization and iBIO Institute Make Notable Additions to Boards of Directors
Illinois Biotechnology Industry Organization and iBIO Institute Make Notable Additions to Boards of Directors
Well-Regarded Scientists, Entrepreneurs and Major Company Executives Bring Great Depth to Leadership Teams
The Illinois Biotechnology Industry Organization—better known as iBIO—and its educational arm, the iBIO Institute, today announced the election of new additions to both companies’ Boards of Directors. The new Board members, who include leading scientists, entrepreneurs, and executives of globally recognized corporations, add depth and prestige to an already-strong lineup of medical, agricultural, industrial and environmental biotech representation.
iBIO Institute Gains Corporate and Academic Expertise
The iBIO Institute named as Chairman of the Board Mark Booth, President of Takeda Pharmaceuticals North America, Inc., the US subsidiary of Takeda Pharmaceutical Company Limited, Japan’s largest pharmaceutical company. Prior to being named President, Booth was formerly an EVP at Takeda, and before that a SVP at Immunex and a Divisional Vice President at Abbott.
Also named to the iBIO Institute Board was Dr. Robert A. “Bob” Easter, Dean of the College of Agricultural, Consumer and Environmental Sciences (ACES) at the University of Illinois. Easter, who was formerly head of the Department of Animal Sciences at University of Illinois, has been a member of the University faculty since 1976 and is considered a leading expert on swine production.
“These are two superb additions to the iBIO Institute Board of Directors,” commented iBIO President & CEO David Miller. “Mark Booth was actively involved in making the BIO 2006 show a great success. Takeda Pharmaceuticals North America is one of the fastest growing pharmaceutical companies in the US and with its newly opened corporate campus in Deerfield has made a demonstrable commitment to the Chicago area and Illinois.”
Miller added, “We are equally excited about recruiting Bob Easter. He is a man of great vision, one who brings immense credibility and academic credentials to the Institute’s ag-bio efforts. Bob Easter has already asserted leadership of our ag-bio strategy work. And he leads one of the top agriculture schools in the world.”
iBIO Board Adds Representation from Startup and Global Biotech, Agriculture Firms
Joining iBIO’s Board are John Benske of Amgen, Gretchen Sue Johnson of KeraCure, Cedric Loiret-Bernal of NanoInk, Bill Moffitt of NanoSphere, John Pieper of Dupont-Pioneer, and Greg Webb of Archer Daniels Midland.
John Benske is Senior Manager, State Government Affairs at Amgen Inc. A veteran biotechnology-pharma state government affairs specialist, he oversees all of Amgen's state legislative and regulatory lobbying activities in an eight state region. Before joining Amgen, Benske held progressively responsible governmental affairs positions for the Pharmacy Society of Wisconsin, TAP Pharmaceuticals, and AstraZeneca. “John Benske for some time now has been one of the biggest contributors to our government affairs effort at iBIO,” commented Board and Executive Committee member Kris Coryell, PhD, Senior Director, Government Affairs and Public Policy at Pfizer. “And it’s great to have a company of Amgen’s stature represented on our Board.”
Gretchen Sue Johnson is a veteran biotechnology and medical device industry executive with more than 15 years experience in the tissue and wound repair industry. Johnson serves as the President and Chief Operating Officer of KeraCure, an emerging biotechnology company commercializing products for the Active Wound Healing Market. She previously served as top sales executive at BioSurface Technologies and as Vice President of Wound Repair at Genzyme Tissue Repair following Genzyme’s acquisition of BioSurface Technologies.
Cédric Loiret-Bernal, M.D. is Chief Executive Officer of NanoInk. Inc., an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life science and other industries. Loiret-Bernal was previously the Chief Executive Officer and co-founder of GeneProt Inc., an industrial-scale proteomics company for which he raised more than $150 million from institutional investors and corporate partners such as Novartis, Compaq (now HP) and Bruker. Prior to GeneProt, he was a Partner and senior investment analyst at Brinson Partners; he also held many other senior positions in corporate strategic planning for Abbott Laboratories, in marketing at Haemonetics and Porgès-Synthélabo.
William P. Moffitt is President and Chief Executive Officer of Nanosphere, Inc. which offers a unique and powerful chemistry that simplifies molecular testing in order to create new standards in discovery, medical care, and public safety. Prior to Nanosphere, Moffitt served as President and Chief Executive Officer of point-of-care diagnostics manufacturer i-STAT Corp. through its IPO in 1992, and its acquisition in 2003 by Abbott Laboratories for $480 million. From 1973 through 1989 Moffitt held increasingly responsible executive positions with Baxter Healthcare Corporation and American Hospital Supply Corporation.
iBIO Chairman Norbert Riedel, CVP and Chief Scientific Officer at Baxter International Inc., hailed the additions to the iBIO Board. “We are very proud that Bill Moffitt, Cedric Loiret-Bernal and Gretchen Sue Johnson, who rank among the region’s top entrepreneurs, are willing to contribute to iBIO’s success as members of our Board of Directors. iBIO is committed to helping enhance the environment for biotechnology startups in the Midwest, and engaging these proven leaders in our work will provide a huge boost to those efforts.”
John Pieper serves as Business Director, for DuPont- Pioneer Hi-Bred International’s Eastern Market. Based in Bloomington, Illinois, he is responsible for sales, marketing, technical services, product logistics and administrative support for the region which includes Illinois, Indiana, Ohio, Pennsylvania, Delaware, and Maryland. Prior to assuming his current position in July of 2006, Pieper held a number of progressively more responsible sales management positions with DuPont Pioneer starting in 1984. He also worked as sales manager at Carrico Implement Company, as a partner and farmer at Sioux View Farms, and in various engineering and marketing roles for Caterpillar Tractor Company.
Gregory W. Webb is Vice President, Public Affairs at Archer Daniels Midland, where he is responsible for relations with business and producer organizations. He joined ADM in 1986, working mostly in the oilseed processing business throughout North America, including soybean, canola, sunflower, flax and cotton. In July 2002, he was named the Company’s North American Trade Representative for Grain and Oilseeds.
“So much of what makes Illinois and the Midwest unique in the life sciences comes from our strong agricultural community, and ADM as well as Dupont-Pioneer are globally recognized firms pursuing critical applications for healthier foods, renewable energy, and environmentally superior industrial products,” commented iBIO President & CEO David Miller. “John Pieper and Greg Webb, two veteran executives with deep experience in this sector, will add substantial depth to our agricultural efforts.
Illinois Biotechnology Industry Organization
The Illinois Biotechnology Industry Organization, also known as iBIO, champions biotechnology in Chicago, Illinois, and the surrounding Midwest region. iBIO’s mission is to strengthen the leadership position of Illinois and the Midwest as a globally recognized life sciences center, a great place to do business, and a great place to start businesses involving advanced technologies. Doing so creates jobs, wealth, and excitement, and contributes to the well being of people worldwide through medical, agricultural, industrial, and environmental applications. To learn more about iBIO and its programs, visit www.ibio.org. iBIO is headquartered in Chicago.
iBIO’s Leadership Sponsors are Abbott, Astellas US, Baxter International, Takeda Pharmaceuticals North America, and TAP Pharmaceutical Products.
iBIO Institute
Based in Chicago Illinois, the iBIO Institute provides education, training and research to the life sciences community and general public. The Institute implements K-12 and community college education programs; training for new and experienced biotechnology workers and entrepreneurs; and outreach to minority and other underserved communities. The iBIO Institute is an IRS certified public charity, and was founded by the Illinois Biotechnology Industry Organization, which champions the life sciences in Illinois and surrounding Midwest. To learn more about the Institute and its objectives, visit www.ibioinstitute.org.
Biotech News
Arizona Biotechnology
Well-Regarded Scientists, Entrepreneurs and Major Company Executives Bring Great Depth to Leadership Teams
The Illinois Biotechnology Industry Organization—better known as iBIO—and its educational arm, the iBIO Institute, today announced the election of new additions to both companies’ Boards of Directors. The new Board members, who include leading scientists, entrepreneurs, and executives of globally recognized corporations, add depth and prestige to an already-strong lineup of medical, agricultural, industrial and environmental biotech representation.
iBIO Institute Gains Corporate and Academic Expertise
The iBIO Institute named as Chairman of the Board Mark Booth, President of Takeda Pharmaceuticals North America, Inc., the US subsidiary of Takeda Pharmaceutical Company Limited, Japan’s largest pharmaceutical company. Prior to being named President, Booth was formerly an EVP at Takeda, and before that a SVP at Immunex and a Divisional Vice President at Abbott.
Also named to the iBIO Institute Board was Dr. Robert A. “Bob” Easter, Dean of the College of Agricultural, Consumer and Environmental Sciences (ACES) at the University of Illinois. Easter, who was formerly head of the Department of Animal Sciences at University of Illinois, has been a member of the University faculty since 1976 and is considered a leading expert on swine production.
“These are two superb additions to the iBIO Institute Board of Directors,” commented iBIO President & CEO David Miller. “Mark Booth was actively involved in making the BIO 2006 show a great success. Takeda Pharmaceuticals North America is one of the fastest growing pharmaceutical companies in the US and with its newly opened corporate campus in Deerfield has made a demonstrable commitment to the Chicago area and Illinois.”
Miller added, “We are equally excited about recruiting Bob Easter. He is a man of great vision, one who brings immense credibility and academic credentials to the Institute’s ag-bio efforts. Bob Easter has already asserted leadership of our ag-bio strategy work. And he leads one of the top agriculture schools in the world.”
iBIO Board Adds Representation from Startup and Global Biotech, Agriculture Firms
Joining iBIO’s Board are John Benske of Amgen, Gretchen Sue Johnson of KeraCure, Cedric Loiret-Bernal of NanoInk, Bill Moffitt of NanoSphere, John Pieper of Dupont-Pioneer, and Greg Webb of Archer Daniels Midland.
John Benske is Senior Manager, State Government Affairs at Amgen Inc. A veteran biotechnology-pharma state government affairs specialist, he oversees all of Amgen's state legislative and regulatory lobbying activities in an eight state region. Before joining Amgen, Benske held progressively responsible governmental affairs positions for the Pharmacy Society of Wisconsin, TAP Pharmaceuticals, and AstraZeneca. “John Benske for some time now has been one of the biggest contributors to our government affairs effort at iBIO,” commented Board and Executive Committee member Kris Coryell, PhD, Senior Director, Government Affairs and Public Policy at Pfizer. “And it’s great to have a company of Amgen’s stature represented on our Board.”
Gretchen Sue Johnson is a veteran biotechnology and medical device industry executive with more than 15 years experience in the tissue and wound repair industry. Johnson serves as the President and Chief Operating Officer of KeraCure, an emerging biotechnology company commercializing products for the Active Wound Healing Market. She previously served as top sales executive at BioSurface Technologies and as Vice President of Wound Repair at Genzyme Tissue Repair following Genzyme’s acquisition of BioSurface Technologies.
Cédric Loiret-Bernal, M.D. is Chief Executive Officer of NanoInk. Inc., an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life science and other industries. Loiret-Bernal was previously the Chief Executive Officer and co-founder of GeneProt Inc., an industrial-scale proteomics company for which he raised more than $150 million from institutional investors and corporate partners such as Novartis, Compaq (now HP) and Bruker. Prior to GeneProt, he was a Partner and senior investment analyst at Brinson Partners; he also held many other senior positions in corporate strategic planning for Abbott Laboratories, in marketing at Haemonetics and Porgès-Synthélabo.
William P. Moffitt is President and Chief Executive Officer of Nanosphere, Inc. which offers a unique and powerful chemistry that simplifies molecular testing in order to create new standards in discovery, medical care, and public safety. Prior to Nanosphere, Moffitt served as President and Chief Executive Officer of point-of-care diagnostics manufacturer i-STAT Corp. through its IPO in 1992, and its acquisition in 2003 by Abbott Laboratories for $480 million. From 1973 through 1989 Moffitt held increasingly responsible executive positions with Baxter Healthcare Corporation and American Hospital Supply Corporation.
iBIO Chairman Norbert Riedel, CVP and Chief Scientific Officer at Baxter International Inc., hailed the additions to the iBIO Board. “We are very proud that Bill Moffitt, Cedric Loiret-Bernal and Gretchen Sue Johnson, who rank among the region’s top entrepreneurs, are willing to contribute to iBIO’s success as members of our Board of Directors. iBIO is committed to helping enhance the environment for biotechnology startups in the Midwest, and engaging these proven leaders in our work will provide a huge boost to those efforts.”
John Pieper serves as Business Director, for DuPont- Pioneer Hi-Bred International’s Eastern Market. Based in Bloomington, Illinois, he is responsible for sales, marketing, technical services, product logistics and administrative support for the region which includes Illinois, Indiana, Ohio, Pennsylvania, Delaware, and Maryland. Prior to assuming his current position in July of 2006, Pieper held a number of progressively more responsible sales management positions with DuPont Pioneer starting in 1984. He also worked as sales manager at Carrico Implement Company, as a partner and farmer at Sioux View Farms, and in various engineering and marketing roles for Caterpillar Tractor Company.
Gregory W. Webb is Vice President, Public Affairs at Archer Daniels Midland, where he is responsible for relations with business and producer organizations. He joined ADM in 1986, working mostly in the oilseed processing business throughout North America, including soybean, canola, sunflower, flax and cotton. In July 2002, he was named the Company’s North American Trade Representative for Grain and Oilseeds.
“So much of what makes Illinois and the Midwest unique in the life sciences comes from our strong agricultural community, and ADM as well as Dupont-Pioneer are globally recognized firms pursuing critical applications for healthier foods, renewable energy, and environmentally superior industrial products,” commented iBIO President & CEO David Miller. “John Pieper and Greg Webb, two veteran executives with deep experience in this sector, will add substantial depth to our agricultural efforts.
Illinois Biotechnology Industry Organization
The Illinois Biotechnology Industry Organization, also known as iBIO, champions biotechnology in Chicago, Illinois, and the surrounding Midwest region. iBIO’s mission is to strengthen the leadership position of Illinois and the Midwest as a globally recognized life sciences center, a great place to do business, and a great place to start businesses involving advanced technologies. Doing so creates jobs, wealth, and excitement, and contributes to the well being of people worldwide through medical, agricultural, industrial, and environmental applications. To learn more about iBIO and its programs, visit www.ibio.org. iBIO is headquartered in Chicago.
iBIO’s Leadership Sponsors are Abbott, Astellas US, Baxter International, Takeda Pharmaceuticals North America, and TAP Pharmaceutical Products.
iBIO Institute
Based in Chicago Illinois, the iBIO Institute provides education, training and research to the life sciences community and general public. The Institute implements K-12 and community college education programs; training for new and experienced biotechnology workers and entrepreneurs; and outreach to minority and other underserved communities. The iBIO Institute is an IRS certified public charity, and was founded by the Illinois Biotechnology Industry Organization, which champions the life sciences in Illinois and surrounding Midwest. To learn more about the Institute and its objectives, visit www.ibioinstitute.org.
Biotech News
Arizona Biotechnology
posted by Famous Quotations - Illinois Biotechnology Industry Organization and iBIO Institute Make Notable Additions to Boards of Directors
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home